Insulet (PODD) Tops Q3 EPS by 12c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Insulet Corporation (PODD) PT Raised to $234 at Barclays
November 11, 2024 5:53 AM ESTBarclays analyst Matt Miksic raised the price target on Insulet Corporation (NASDAQ: PODD) to $234.00 (from $220.00) while maintaining a Equalweight rating.
The analyst comments "PODD Rallies on Q3 Beat, Fueled by International (+$19MM), Drug Delivery (+$7MM) and Rising Expectations for the T2 Pump Launch: Mgmt delivered a strong beat to vs. our estimates and Bloomberg... More
Insulet Corporation (PODD) PT Raised to $270 at BTIG
November 8, 2024 5:13 AM ESTBTIG analyst Marie Thibault raised the price target on Insulet Corporation (NASDAQ: PODD) to $270.00 (from $260.00) while maintaining a Buy rating.
The analyst comments "Insulet reported Q3 revenue of $543.9M (+25.7% y/y), beating consensus estimates of $519.5M and exceeding the ~$510-$524M sales guide. This was driven by a large beat in International Omnipod sales. U.S. Omnipod revenue of $395.6M came in ~$4M higher than expected (cons. $391.9M) while OUS Omnipod revenue of $138M was ~$15M above the Street's forecast (cons. $123.3M). Drug Delivery sales were $10.3M. The full year sales guide... More
